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Abstract
 
Many tumors overexpress members of the inhibitor of apoptosis protein (IAP) family. IAPs
contribute to tumor cell apoptosis resistance by the inhibition of caspases, and are degraded by
the proteasome to allow further progression of apoptosis. Here we show that tumor cells can
alter the specificity of cytosolic proteolysis in order to acquire apoptosis resistance, which pro-
motes formation of rapidly growing tumors. Survival of tumor cells with low proteasomal ac-
tivity can occur in the presence of high expression of Tri-peptidyl-peptidase II (TPP II), a large
subtilisin-like peptidase that complements proteasomal activity. We find that this state leaves
tumor cells unable of effectively degrading IAPs, and that cells in this state form rapidly grow-
ing tumors in vivo. We also find, in studies of apoptosis resistant cells derived from large in
vivo tumors, that these have acquired an altered peptidase activity, with up-regulation of TPP
II activity and decreased proteasomal activity. Importantly, we find that growth of subcutane-
ous tumors is limited by maintenance of the apoptosis resistant phenotype. The apoptosis re-
sistant phenotype was reversed by increased expression of Smac/DIABLO, an antagonist of
IAP molecules. Our data suggest a reversible mechanism in regulation of apoptosis resistance
that drives tumor progression in vivo. These data are relevant in relation to the multitude of
therapy-resistant clinical tumors that have increased levels of IAP molecules.
Key words: apoptosis • proteasome • tri-peptidyl-peptidase II • IAP • caspase
 
Introduction
 
Ubiquitinated proteins are degraded by the 26S protea-
some, a large multi-catalytic protease complex present in
the cytosol and nucleus of mammalian cells (1–3). This
complex contains a catalytic core (20S) and an accessory
complex (19S) that recognizes ubiquitinated substrates and
translocates these to the catalytic sites in the 20S particle
(4). The proteasome is responsible for most of cytosolic
protein degradation in eukaryotic cells, of both short-lived
and long-lived proteins, and some of the degradation frag-
ments are presented bound to MHC class I molecules (1).
However, substantially less than full proteasomal activity is
required for sustained viability of mammalian cells, thus in-
dicating the presence of an over-capacity for proteasomal
proteolysis (5–8). This could be used in situations of in-
creased demand for protein degradation such as heat shock,
or alternatively it may be necessary to assure a distinct tim-
ing in degradation of regulatory factors. However, it is not
clear why this excess in proteolytic capacity exists and
whether it is necessary for control of cellular pathways reg-
ulated by proteasomal protein degradation.
Proteasomal inhibition (
 
 
 
80%), and other types of cellu-
lar stress, causes release of cytochrome c from mitochondria
into the cytosol and triggers assembly of the apoptosome
(5, 9–11). Regulatory factors controlled through the ubiq-
uitin–proteasome pathway control these events, including
mitochondrial release of cytochrome c and subsequent acti-
vation of caspases (9–13). Inhibitor of apoptosis proteins
(IAPs)
 
*
 
 are endogenous caspase inhibitors, which must be
degraded by the proteasome to allow further progression of
apoptosis (12, 13). Increased in vivo expression of IAPs
leads to suppression of normally occurring cell death in
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 IAP, inhibitor of apoptosis protein; NLVS,
nitro-phenol-tri-leucine-vinyl-sulphone; TPP II, tri-peptidyl-peptidase II.T
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both mammals and insects (14, 15). Proteins of the IAP
family contain baculoviral IAP repeat (BIR)-domains by
which they can bind to and inhibit caspases and thereby
rescue cells from apoptosis. Several members of this family,
e.g., XIAP, c-IAP-1, and Survivin, are frequently up-regu-
lated in tumor cells, where they cause resistance to cancer
therapy due to inhibition of tumor cell apoptosis (16–18).
Inhibitors of the proteasome can transiently inhibit apopto-
sis due to accumulation of IAPs, but cell cycle arrest and
apoptosis eventually follows (11, 13). As cells may grow
with reduced proteasomal activity, and even with much re-
duced activity when compensatory proteolysis is induced
(6–8), it appears possible that this may be involved in the
control of IAP expression. Cellular viability in the presence
of inhibited proteasomal activity may be allowed by in-
creased activity of Tri-peptidyl-peptidase II (TPP II, 19), a
large subtilisin-like peptidase that is believed to degrade
polypeptides downstream of proteasomal protein degrada-
tion (6–8). Increased activity of TPP II is sufficient to
maintain proliferation of EL-4 lymphoma cells when the
proteasome is inhibited, but it is not clear whether this state
has any consequences for pathways controlled by ubiq-
uitin-dependent proteolysis (8). This state is also observed
in Epstein Barr virus–transformed B cells overexpressing
c-myc, but it is unknown whether this has any impact on
tumor progression (20).
In this paper we have studied apoptosis control in tumor
cells with high TPP II activity, which can grow despite
proteasomal inhibition. Several studies have implicated a
high expression of 20S proteasomes in tumor cells, in line
with a high demand for proteolysis in rapidly proliferating
cells (21, 22). However, death by apoptosis balances cellu-
lar proliferation, and resistance to apoptosis may be at least
as important as the rate of proliferation for growth of the
tumor tissue (23). We find that EL-4 lymphoma cells that
can grow in the presence of low proteasomal activity ac-
quire apoptosis resistance due to a failure in degradation of
IAPs. The rate of in vivo tumor growth of such cells was
strongly increased. Rapid tumor growth, as well as a de-
layed degradation of IAPs, could be induced by transfection
of TPP II. In addition, in cells derived from large in vivo
tumors we observe a slower degradation of IAPs, as well as
well as a reduced activity of the proteasome in combination
with up-regulated TPP II activity. Our data suggest a novel
mechanism for apoptosis resistance in tumors.
 
Materials and Methods
 
Cells and Transfections.
 
EL-4 is a Benzopyrene-induced
mouse T cell lymphoma derived from C57Bl/6. EL-4 control
and EL-4ad cells were maintained in vitro in RPMI 1640 supple-
mented with 5% FCS, and 50 
 
 
 
M of nitro-phenol-tri-leucine-
vinyl-sulphone (NLVS; reference 24) for EL-4ad cells. EL-4ad
cells were obtained by seeding control EL-4 cells at 10
 
5
 
/ml in 12-
well plates and continuously incubated in 10 
 
 
 
M NLVS. This
treatment blocks all active 
 
 
 
-subunits except for Z/MECL-1, and
kills most cells within 24–48 h. However, a subpopulation
adapts to grow progressively within 2–3 wk (6). The concentra-
 
tion of NLVS is then gradually increased to 50 
 
 
 
M. EL-4 cells
adapted to growth in starvation medium were first incubated in
medium containing RPMI 1640 supplemented with 2.5% FCS
and 50% PBS; and the cells were then gradually adapted to resist
culture in 75% PBS, similarly to what has been described previ-
ously (25). EL-4ad transfectants with pEF control vector or pEF/
DIABLO were generated by incubation with 5 
 
 
 
g/ml Lipo-
fectamine
 
®
 
 (Life Technologies) and transfectants were selected by
8 
 
 
 
g/ml Puromycin. The pcDNA3 and pcDNA3-TPP II-trans-
fectants of EL-4 are described previously (8).
 
Tumor Growth Experiments.
 
Tumor cells were washed in PBS
and resuspended in a volume of 200 
 
 
 
l per inoculate. The cells
were then inoculated into the right flank at 10
 
5
 
 or 10
 
6
 
 per syngeneic
C57Bl/6 mouse and growth of the tumor was monitored by mea-
surement 1–2 times per week. The mice were irradiated with 400R
before tumor inoculation in order to inhibit antitumor immune re-
sponses. The tumor volume was calculated as the mean volume in
mice with tumors growth, according to (a
 
1
 
 
 
 
 
 a
 
2
 
 
 
 
 
 a
 
3
 
)/2 (the num-
bers a
 
i
 
 denote tumor diameter, width and depth). The data represent
tumor volume in mice with growing tumors, and mice that rejected
the tumor cells at inoculation were thus excluded. EL-4/tumor cells
were derived from tumors of at least 1 cm
 
3
 
 and were cultured in
RPMI supplemented with 5% FCS a few days in vitro before ex-
periments to exclude confounding factors such as rate of growth,
nutritional state and contaminating nontumor cells.
 
Apoptosis Induction and DNA Fragmentation Assays.
 
For in-
duction of apoptosis we used serum starvation (RPMI/0.1%
FCS), 10 nM TNF-
 
 
 
, 25 
 
 
 
M etoposide, or 1 
 
 
 
M Nocodazole.
Cells were seeded at 10
 
6
 
 cells/ml in 12-well plates and incubated
for 18 h. DNA from EL-4 control and adapted cells were purified
by standard Chloroform extraction and 2.5 
 
 
 
g of DNA was
loaded on 1.8% agarose gel for detection of DNA from apoptotic
cells. For analysis of caspase activation we used the following
short reporter peptide substrates: DEVD-AFC (caspase 3),
LETD-AFC (caspase 8), and LEHD-AFC (caspase 9; Enzyme
Systems Products). All apoptosis assays were made several times
and representative data were chosen for display. EL-4ad
 
 
 
 are EL-
4ad cells that were washed from inhibitor and culture for three
weeks in vitro
 
,
 
 in RPMI1640 supplemented with 5% FCS, in the
absence of NLVS.
 
Antibodies and Western Blot Analysis.
 
We used the following
reagents for detection with standard Western blot analysis tech-
niques: rabbit anti-cytochrome c serum (Santa Cruz Biotechnol-
ogy, Inc.); 4G10 monoclonal anti-SMAC/DIABLO (Alexis
Corporation); anti-ubiquitin (DakoCytomation); affinity-puri-
fied rabbit anti-mouse XIAP (R&D Systems); CH9 anti-protea-
somal subunit 
 
 
 
3 (Affiniti Research Products Limited). Chicken
anti-TPP II serum (Immunsystem). Protein concentration was
determined with BCA Protein Assay Reagent (Pierce Chemical
Co.), and 5 
 
 
 
g of protein was loaded per lane for separation by
SDS/PAGE.
 
Heat Shock Incubation and Degradation of Ubiquitinated Proteins.
 
EL-4/tumor cells were obtained from killed C57Bl/6 mice with
large (
 
 
 
1 cm
 
3
 
) tumors, by excising pieces and that were put into
single cell suspension, and were cultured in vitro for 2–4 d.
Larger tumor sizes were chosen for analysis, as this increases the
requirements for nutrion and oxygen supply in growing tumor
tissue in vivo. 10
 
6
 
 EL-4/tumor, EL-4, EL-4ad cells, and C57Bl/6
Con A blasts were exposed to 42
 
 
 
C for 30 min and aliquots of
cells were either lysed directly or after 30 min, 4 and 16 h of in-
cubation at 37
 
 
 
C. The levels of ubiquitin-conjugates were evalu-
ated by Western blot analysis of cell lysates with anti-ubiquitin
anti-serum (DakoCytomation).T
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Protein Purification and Peptidase Assays.
 
100 
 
 
 
 10
 
6
 
 cells were
sedimented and lysed by vortexing in glass beads and homogeni-
zation buffer (50 mM Tris Base, pH 7.5, 250 mM Sucrose, 5 mM
MgCl
 
2
 
, 1 mM DTT). Cellular lysates were submitted to differen-
tial centrifugation where a supernatant from a 1 h centrifugation
at 100,000 
 
g
 
 (cytosol) was submitted to 100,000 
 
g
 
 centrifugation
for 5 h, which sedimented high molecular weight cytosolic pro-
teins/protein complexes, 
 
 
 
5% of the cytosolic protein. The re-
sulting pellet dissolved in 50 mM Tris Base, pH 7.5, 30% Glyc-
erol, 5 mM MgCl
 
2
 
, and 1 mM DTT, and 1 
 
 
 
g of high molecular
weight protein was used as enzyme in peptidase assays. To test
the activity of the proteasome and TPP II we used the substrates
succinyl-LLVY-AMC and AAF-AMC (Sigma-Aldrich), respec-
tively, at 100 
 
 
 
M concentration in 100 
 
 
 
l of test buffer com-
posed of 50 mM Tri Base pH 7.5, 5 mM MgCl
 
2
 
, and 1 mM
DTT. Cleavage activity was measured by emission at 460 nm in a
LS50B Luminescence Spectrometer (PerkinElmer). Peptidase ac-
tivity of high molecular weight proteins was tested three times
and representative data were chosen for display.
 
Results
 
Cells that Grow with Low Proteasomal Activity Are Resistant
to Apoptosis.
 
We used EL-4ad, a variant cell line of EL-4,
that grow in the presence of a covalent proteasome inhibi-
tor (NLVS; references 6 and 24). We tested whether EL-
4ad cells were able to properly control apoptosis induction,
as this normally follows when cells are grown in the pres-
ence of proteasomal inhibitors (11). We observed that EL-
4ad cells failed to undergo apoptosis when exposed to se-
rum starvation for 36 h, and even continued low levels of
proliferation (Fig. 1, b–d). Furthermore, EL-4ad responded
very poorly to TNF-
 
 
 
 and etoposide in comparison to EL-4
control cells, as shown by inefficient activation of caspases
3, 8, and 9 as well as absence of DNA fragmentation (Fig.
2, a-c). However, after culture of EL-4ad in the absence of
proteasomal inhibitor the apoptosis resistance was reversed,
and DNA fragmentation was again observed in response to
TNF-
 
 
 
 and etoposide (Fig. 2 d). This reversal was ob-
served 2–3 wk after removal of the proteasomal inhibitor,
and coincided with a regained dependence of proteasomal
proteolysis in EL-4ad (unpublished data). These data sug-
gest that EL-4 cells may acquire apoptosis resistance
through an altered specificity of cytosolic proteolysis.
A multitude of ubiquitin-dependent regulatory factors
control apoptosis, either upstream or downstream of mito-
chondrial cytochrome c-release (9, 10, 12, 13). To test
whether cytochrome c was released from mitochondria
during cellular stress in EL-4ad cells we exposed these to
serum starvation for up to 36 h. We detected cytosolic cy-
tochrome c after 36 h of serum starvation in both EL-4
control and EL-4ad cells, by Western blot analysis of puri-
fied cytosols (Fig. 1 e). The ability of EL-4ad to maintain
some proliferation despite initiation of the apoptotic pro-
gram bears resemblance to observations made in mice defi-
cient for caspase 9 (26). Our results suggest the presence of
factors that inhibit apoptosis downstream of mitochondrial
cytochrome c-release in EL-4ad cells. As cleavage of PARP
was inhibited in EL-4ad, these results also suggest that these
factors work upstream to nuclear DNA fragmentation (Fig.
1 f).
 
Failure to Degrade IAP Molecules Causes Apoptosis Resis-
tance in Growing EL-4ad Cells.
 
Many reports describe that
IAPs must be degraded by the proteasome subsequently to
mitochondrial cytochrome c release to allow activation of
Figure 1. Resistance to serum starvation-induced apoptosis in cells
adapted to reduced proteasomal activity. (a) Chymotryptic proteasomal
activity in EL-4 and EL-4ad measured by cleavage of succinyl-LLVY-
AMC in fractions of high molecular weight cytosolic protein eluted from
a Superose 6 column. (b) DNA fragmentation measured during growth of
EL-4 control and EL-4ad cells in normal cell culture medium (5% FCS)
and in serum starvation medium (0.1% FCS). (c and d) Proliferation of
EL-4 and EL-4ad cells in normal cell culture medium (c) versus serum
starvation medium (d). (e) Western blot analysis for cytochrome c using 5
 g of cytosols from EL-4 and EL-4ad cells growing in normal (5% FCS)
or serum starvation medium (0.1% FCS). (f) Western blot analysis for
PARP in EL-4 and EL-4ad cells treated with etoposide.T
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caspase 9, and further progression into apoptosis (12–18).
We tested if EL-4ad could degrade XIAP, a 56 kD endog-
enous antagonist of caspase 9, in response to etoposide
treatment. We found degradation of XIAP in EL-4 cells,
whereas this was very slow in EL-4ad cells (Fig. 3 a). In
EL-4ad cells, a substantial accumulation of XIAP was ob-
served already before apoptosis, in comparison to EL-4
control cells, which may further inhibit caspase activation
(Fig. 2, b and c). Culture of EL-4ad cells in the absence of
NLVS makes EL-4ad dependent of proteasomal proteoly-
sis. This accelerated degradation of XIAP (Fig. 3 a). We
further found that c-IAP-1 was similarly induced and deg-
radation was slow after etoposide treatment of EL-4ad cells
(unpublished data). Thus, we find that the altered specific-
ity of cytosolic proteolysis causes slow degradation of IAP
molecules in EL-4ad cells.
To test if the apoptosis resistance of EL-4ad cells de-
pended on IAP molecules we used Smac/DIABLO, an IAP-
inactivator (27–29). Smac/DIABLO is released through
the outer mitochondrial membrane together with cyto-
chrome c, and binds to IAP molecules to prevent their in-
hibitory effect on caspase activation (29, 30). Further,
Smac/DIABLO is also reported as necessary for apoptosis
induction in prostate cancer cells (31). EL-4ad cells trans-
fected with pEF-Smac/DIABLO obtained increased Smac/
DIABLO-expression, as detected by the specific mAb
4G10, using empty pEF vector-transfected cells as control
(Fig. 3 b). During normal culture conditions (5% FCS) this
increased Smac/DIABLO expression had minor effects on
EL-4ad, as the rate of proliferation could not be distin-
guished from pEF control vector-transfected EL-4ad cells.
However, a substantial effect was observed during serum
starvation, showing a reduced proliferation of Smac/DI-
ABLO-transfected EL-4ad cells in comparison to pEF con-
trol vector-transfected cells (Fig. 4 a). During triggering of
apoptosis with Etoposide we found that caspase 9 and
3-activation as well as DNA fragmentation was restored in
EL-4ad cells transfected with pEF-Smac/DIABLO, but not
pEF empty vector (Fig. 3, c and d). A set of three addi-
tional EL-4ad lines transfected with either pEF empty vec-
tor or pEF-Smac/DIABLO were analyzed for DNA frag-
mentation and caspase 9 activity, with similar results (Fig.
4). By using Smac/DIABLO, our data suggest that the in-
adequate degradation of IAP molecules inhibit the trans-
duction of apoptotic signals in EL-4ad cells.
 
EL-4 Cells Adapted to Low Proteasomal Activity Form Rap-
idly Growing In Vivo Tumors.
 
Apoptosis resistance medi-
ated by IAP molecules is frequently observed in tumor
cells, and is regarded as a major problem during tumor
therapy (16–18, 32–35). We did not observe an increased
growth rate for EL-4ad cells, whereby IAP-mediated apop-
tosis resistance does not appear to be a significant growth
Figure 2. Reversible apoptosis resistance induced by
adaptation to reduced proteasomal activity. (a) DNA
fragmentation in EL-4 control and EL-4ad cells ex-
posed to 10 nM TNF-  (left panel) or 25  M Etopo-
side (right panel). (b and c) The activities of caspases 8,
9, and 3 in response to treatment with 10 nM TNF- 
(b) or 25  M Etoposide (c) were tested in parallel. The
data represent the mean out of three independent ex-
periments, where the background in EL-4 control cells
was normalized to 100%. Standard deviation is indi-
cated. (d) Loss of apoptosis resistance after culture in
the absence of proteasomal inhibitor, as measured by
DNA fragmentation in response to TNF-  or Etopo-
side. EL-4 control (lanes labeled 1), EL-4ad (2), and
EL-4ad , i.e., EL-4ad cultured without NLVS (3)
were compared in indicated lanes.T
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advantage during in vitro cell culture (Fig. 1, c and d). Sub-
cutaneous tumor growth in vivo may expose growing cells
to more stress (e.g., competition for nutrients and oxygen),
and we therefore tested in vivo growth of EL-4 control and
EL-4ad cells by inoculation into irradiated syngeneic
C57Bl/6 mice (Fig. 5, a and b). We found that tumors of
Figure 3. Inhibited proteasomal degradation of IAP
molecules contributes to apoptosis resistance in EL-4ad
cells. (a) XIAP expression in EL-4, EL-4ad, and EL-4ad 
cells after treatment with 25  M Etoposide. EL-4ad 
denotes EL-4ad cells that were cultured in the absence
of NLVS. XIAP molecules were detected by Western
blot analysis of 5  g of cellular lysates from the indi-
cated cell lines. As loading controls,  -actin was
probed. (b) Smac/DIABLO-expression in EL-4ad cells
transfected with either pEF control vector or pEF-
DIABLO. (c and d) Reversal of EL-4ad apoptosis resis-
tance by Smac/DIABLO as measured by DNA frag-
mentation (c) and Caspase activation (d).
Figure 4. Reversal of apoptosis resistance in an
expanded set of Smac/DIABLO-transfectant EL-4ad
lines. (a) Proliferation of EL-4ad-pEF and EL-4ad-
pEF/DIABLO cells was measured during normal
(5% FCS) or conditions of serum starvation (0.1%
FCS). The data represent the mean of proliferation
of four independently transfected lines. (b and c).
Reversal of EL-4ad apoptosis resistance in three in-
dependently transfected Smac/DIABLO-trans-
fected lines, as measured by DNA fragmentation
(b) and Caspase 3 activation following exposure to
Etoposide (c).T
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EL-4ad cells were rapidly growing and reached a size of 
 
 
 
1
cm
 
3
 
 in 30 d (Fig. 5 a). In contrast, growth of EL-4 tumors
was significantly slower and did not reach more than 0.2–
0.3 cm
 
3
 
 during this time period. Using a lower cell dose
than initially used, the difference in growth rate between
EL-4 and EL-4ad tumors was even more evident (Fig. 5 b).
Although the differences between EL-4 and EL-4ad tu-
mors were clear, at later stages the growth rate of EL-4
control tumors reached the same as observed for tumors of
EL-4ad (Fig. 5 a). Therefore we killed animals and excised
cells from large (
 
 
 
1 cm
 
3
 
, as indicated in Fig. 5 a) in vivo
tumors for later analysis
 
.
 
 Importantly, we found that rapid
growth of subcutaneous EL-4 tumors was linked to apop-
tosis resistance, as Smac/DIABLO-transfection of EL-4ad
cells reduced tumor growth rate, in comparison to tumors
of pEF-control vector transfected cells (Fig. 5 c). Increased
growth of EL-4ad tumors, compared with EL-4 control,
was present also in immunodeficient mice (PKOB/
RAG
 
 
 
/
 
 
 
; Fig. 5 d). Thus, EL-4 lymphoma cells with an al-
tered specificity of cytosolic proteolysis have a growth ad-
vantage in vivo over control EL-4 cells.
 
Increased TPP II Activity Reduces IAP Degradation and In-
duces Rapid Tumor Growth In Vivo.
 
We next studied
whether proteolytic pathways accessory to the proteasome,
that are up-regulated in EL-4ad cells, could alter the degra-
dation of IAP molecules. For this purpose we used EL-4
wild type cells transfected with either control vector,
pcDNA3, or with pcDNA3-TPP II, described previously
(8). TPP II transfection conferred a reduced reliance of
proteasomal proteolysis, since EL-4.TPP II proliferated in
the presence of NLVS, whereas as EL-4pcDNA3 cells did
not (Fig. 6 a). In addition we observed that EL-4.TPP II
proliferated in the presence of 50 
 
 
 
M AdaAhx
 
3
 
L
 
3
 
VS, a
novel amino-terminally extended vinyl sulphone that in-
hibits all 
 
 
 
-subunits (B
 
1
 
, B
 
2
 
, and B
 
5
 
) with comparable effi-
ciency (36, 37; Fig. 6 b). These data confirm previous find-
ings that up-regulation of TPP II allows EL-4 cells to use
minimal proteasomal 
 
 
 
-subunit activity and still manage
cellular proliferation (6–8, 37).
We next tested if TPP II affected the response to an apop-
totic stimulus by exposing EL-4pcDNA3 and EL-4.TPP II
cells to etoposide. We found by Western blot analysis of
cellular lysates that EL-4.TPP II failed to fully degrade
both XIAP and c-IAP-1 compared with EL-4pcDNA3
cells during etoposide treatment (Fig. 7, a and b). Further,
whereas DNA fragmentation was induced in EL-
4pcDNA3 cells this effect was not present in EL-4.TPP II
36 h after onset of apoptosis. Thus, adequate apoptosis
control was not maintained in EL-4.TPP II. Further, treat-
ment of EL-4.TPP II with 50 
 
 
 
M NLVS, a treatment that
allows survival of most EL-4.TPP II cells (Fig. 6 a), led to a
substantially increased level of XIAP and c-IAP-1 (Fig.
7 a). The same treatment of EL-4pcDNA3 control cells,
lacking up-regulation of accessory proteolysis, caused a
transient increase of XIAP and c-IAP-1, but failed to pro-
tect from apoptosis over an extended period of time (Figs.
7 b and 6 c).
To explore whether increased TPP II activity regulated
the growth of EL-4 tumors in vivo we tested growth of
EL-4.pcDNA3 and EL-4.TPP II tumors in syngeneic
C57Bl/6 mice after subcutaneous inoculation. Although
no differences in proliferation rate were found in vitro, EL-4
cells with increased TPP II-expression (EL-4.TPP II) had a
strongly increased rate of in vivo growth compared with
tumors transfected with pcDNA3 control vector (Fig. 6 d).
This supports the notion that apoptosis resistance linked to
TPP II was responsible for the observed effects on growth
of EL-4 tumors in vivo
 
.
 
These results are in line with previous studies showing
that proteasomal inhibition can confer a transient apoptosis
Figure 5. Rapid tumor growth by EL-4 cells adapted to
low proteasomal activity. (a-d) EL-4 and EL-4ad cells were
grafted at 106 or 105 cells, as indicated in figure, in synge-
neic C57Bl/6 mice and tumor size was monitored. (a and
b) Tumor growth of EL-4 and EL-4ad cells in syngeneic
C57Bl/6 mice. EL-4/tumor in panel a denotes cells re-
moved from killed mice to be analyzed further in Figs. 8
and 9, (c) Tumor growth of EL-4ad cells transfected with
either pEF control vector or with pEF-Smac/DIABLO.
(d) Tumor growth of EL-4 and EL-4ad cells in immuno-
deficient PKOB/RAG1 /  mice, deficient for T and B
cells as well as NK cell cytotoxic activity. The data repre-
sent the mean of at least eight mice per group in a-c,
whereas four mice per group were used in d.T
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resistance by a failure to degrade IAPs, although subsequent
apoptosis is observed due to requirement for efficient pro-
teasomal 
 
 
 
-subunit activity for cellular viability (11, 13). In
addition, these results show that increased TPP II expres-
sion interferes with efficient XIAP and c-IAP-1 degrada-
tion in EL-4 cells, a state not compatible with efficient
transduction of apoptotic signals (12, 13). Inhibition of the
proteasome with NLVS in EL-4.TPP II leads to a further
accumulation of IAPs without subsequent apoptosis.
 
Selection of Altered Peptidase Activity and Delayed IAP
Degradation during In Vivo Tumor Growth.
 
Previous results
have shown that tumor cells, as well as immature blasts, ex-
press high levels of 20S proteasomes, in line with the high
demand for proteolysis in rapidly growing cells (21, 22).
This is also in line with rapid cell cycle progression in tu-
mor cells by efficient degradation of regulatory factors at
cell cycle checkpoints. This may be one reason for the
therapeutic effect of proteasomal inhibitors to some forms
of cancer (38, 39). However, it could be possible that
growth conditions that are more in favor for apoptosis re-
sistant cells could show selection of a phenotype that more
resembles the one observed in EL-4ad cells. We have ob-
served that an altered specificity of cytosolic proteolysis
causes apoptosis resistance in EL-4 cells (Figs. 1 and 6), and
also that rapid in vivo growth of EL-4 tumors favored
growth of such cells (Fig. 5). Therefore we examined the
activity of the proteasome and TPP II in EL-4 control cells
before and after growth in subcutaneous tumors in vivo.
Partial purifications of high molecular weight proteins
from EL-4 control cells, EL-4ad, and EL-4 cells derived
from large (
 
 
 
1 cm
 
3
 
) in vivo tumors (denoted EL-4/tu-
mor) were prepared, and these were tested for cleavage of
Figure 6. TPP II transfection confers resistance to proteasomal inhibition and reduces IAP degradation. (a and b) EL-4 cells transfected with pcDNA3
control vector or pcDNA3-TPP II, were treated either with NLVS (a) or with AdaAhx3Leu3VS (b). Whereas NLVS (reference 24) inhibits predomi-
nantly the chymotryptic activity of the proteasome, AdaAhx3Leu3VS (reference 37) inhibits all proteasomal  -subunits with comparable efficiency.
Cellular proliferation was measured daily by counting live cells by trypan blue exclusion, and the data represent the mean from two independent ex-
periments. (c) EL-4 cells transfected with either pcDNA3 or pcDNA3-TPP II were treated with Etoposide and DNA fragmentation was followed for up
to 36 h. (d) Tumor growth of 106 EL-4pcDNA3 and EL-4.TPP II cells in vivo in syngeneic C57Bl/6 mice. Growth was monitored weekly, and the data
represent the mean out of two independent experiments with a total of six mice per group.
Figure 7. Increased expression of TPP II allows accumulation of IAP
molecules. (a) EL-4.pcDNA3 and (b) EL-4.TPP II were either treated
with 50  M NLVS or not. Then, these two groups were exposed to
Etoposide and degradation of XIAP and c-IAP-1 was followed by West-
ern blot analysis of 5  M of cellular lysate.  -actin was Western blotted as
loading controls.T
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peptide substrates preferred by either TPP II (AAF-AMC)
or the proteasome (succ-LLVY-AMC). We found that
high molecular weight peptidases in EL-4/tumor cells had
increased cleavage of AAF-AMC and reduced cleavage of
succ-LLVY-AMC, compared with EL-4 control cells (Fig.
8 a). This activity profile corresponded to increased TPP II
activity and reduced proteasomal activity, as determined
by specific inhibitors of either the proteasome or TPP II
(24, 40). Interestingly, we found the same pattern of pepti-
dase activities in cells derived from subcutaneous tumors of
ALC lymphoma and B16 melanoma (Fig. 8, b and c).
Thus, we observed an altered activity of the proteasome
and TPP II in cells derived from large in vivo tumors, al-
though the alterations of peptidase activities were not as
pronounced as in EL-4ad cells (Fig. 8, a-c). In line with
this, EL-4 cells derived from these in vivo tumors were
still dependent on proteasomal activity since they did not
grow in the presence of NLVS (Fig. 8 e). The levels of
proteasomal  -subunit protein in the tumor-derived cells
(EL-4, ALC, and B16) were not significantly different, in
comparison to in vitro grown cells, suggesting a post-
translational regulation of 20S proteasomal activity (Fig. 8
f; reference 41).
To test the efficiency of IAP degradation following initi-
ation of apoptosis in EL-4/tumor cells, we treated these
with etoposide and compared the removal of XIAP and
c-IAP-1 to that present in EL-4 control and EL-4ad cells.
In line with the observed peptidase activities, we observed
an inefficient degradation of both XIAP and c-IAP-1 in
EL-4/tumor cells whereas these IAPs were effectively de-
graded in EL-4 control cells. We further observed a weak
induction of DNA fragmentation in EL-4/tumor cells in
comparison to EL-4 control cells, showing an ineffective
transduction of the apoptotic signal (Fig. 9 a). These data
support the notion that an altered specificity of cytosolic
proteolysis is selected in apoptosis resistant tumors in vivo.
We next tested the ability of EL-4ad and EL-4/tumor
cells to remove ubiquitin conjugates, since ubiquitin con-
jugation of regulatory factors controls transduction of ap-
optotic signals. We exposed these cells to heat shock (42 C,
Figure 8. Altered activity of high molecular weight peptidases during tumor growth. (a–c) Measurements of high molecular weight peptidase activity
in cell lines derived from in vitro cultures and in vivo tumors derived from (a) EL-4, (b) ALC lymphoma, and (c) B16 melanoma. Inhibitors specific for
either the proteasome (NLVS; reference 24) or TPP II (Butabindide; reference 40), were used to identify the activities cleaving succinyl-LLVY-AMC
and AAF-AMC. (d) Activity of high molecular weight peptidases measured in EL-4.pcDNA3 and EL-4.TPP II, experiments performed as in a–c. (e) In
vitro growth rate of EL-4, EL-4ad versus EL-4/tumor cells in the presence or absence of 5  M NLVS, as measured by counting live cells by trypan blue
exclusion. (f) Western blotting of high molecular weight proteins for HC9, a proteasomal  -subunit ( 3). 2, 5, or 10  g of protein was loaded in each
lane, as indicated in figure.T
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30 min) and followed removal of ubiquitin conjugates by
Western blot analysis of cellular lysates, in comparison to
EL-4 control cells treated similarly. We found that both
EL-4/tumor cells and EL-4ad cells had great difficulties in
clearing heat shock-induced ubiquitin conjugates, in com-
parison to EL-4 control cells. Thus, although compensa-
tory proteolysis is induced in EL-4ad and EL-4/tumor
cells, this appears to be less efficient in removing ubiquitin-
conjugates than the proteasome. In contrast, C57Bl/6 Con
A blasts readily cleared the ubiquitin conjugates within
16 h, showing that this feature was specific for malignant
but not for normal lymfoblasts (Fig. 8 d). We note that hy-
perthermia is a method that is sometimes used in clinical
treatment of tumors (42).
Cellular Growth with Insufficient Nutrition Increases TPP II
Activity and Resistance to Apoptosis. It has been proposed
that poor nutritional conditions in the tumor microenvi-
ronment contributes to selection of apoptosis resistant cells
(43). As increased expression of TPP II conferred a partial
protection from apoptosis of EL-4 cells, and induced rapid
tumor growth in vivo (Fig. 6), we set out to test if poor
nutritional conditions may affect the activity of TPP II in
tumor cells. For this purpose we adapted EL-4 cells for
long-term survival in starvation medium with reduced
content of amino acids and growth factors (25). EL-4 con-
trol cells and EL-4 cells growing in starvation medium
were lysed and high molecular weight proteins were pre-
pared for Western blot analysis and enzymatic activity as-
says. By analysis with anti-TPP II serum we found high
levels of TPP II protein among cytosolic high molecular
weight proteins in EL-4 cells growing in starvation me-
dium, and this induction was observed already after short–
term incubation (20 h, Fig. 10 a). This also correlated with
a strong increase in enzymatic activity cleaving AAF-AMC
(Fig. 10 c). Further, EL-4 cells adapted to proliferation in
starvation medium were resistant to apoptosis and ex-
pressed high levels of c-IAP-1; and this was not properly
degraded upon treatment with etoposide (Fig. 10 b, un-
published data). These data fit well with the notion that
apoptosis resistance mediated by IAP molecules allows a
limited proliferation during serum starvation (Fig. 4 a).
Finally, in order to further test if adaptation to growth in
starvation medium affected tumor growth of these EL-4
cells in vivo, we grafted 106 or 104 EL-4 control cells versus
EL-4 cells adapted to growth in starvation medium to
C57Bl/6 mice. We found that EL-4 cells adapted to starva-
tion medium had an increased rate of tumor growth, espe-
cially in inoculates with lower cell numbers (104), further
substantiating that this adaptation is used to increase the
growth of EL-4 tumors in vivo (Fig. 10 d). Thus, TPP II
has a substantial influence on EL-4 tumor growth in vivo,
and is also regulated in response to the nutritional state of
the microenvironment.
Discussion
These data suggest that an alteration in the activity of
proteolytic pathways that are responsible for cellular pro-
tein turn-over contributes to apoptosis resistance in tumor
cells. EL-4 cells adapted to low proteasomal activity, de-
noted EL-4ad, were resistant to apoptosis, at least in part
due to a failure in efficient degradation of IAP molecules,
and EL-4 cells with this phenotype grew rapidly as tumors
in vivo. Our data also show that up-regulation of TPP II, a
peptidase that allows EL-4 cells to grow with low proteaso-
mal activity, leads to rapid tumor growth in vivo. The ob-
served EL-4 apoptosis resistance phenotype was reversible,
and was not present when not selected for, such as during
optimal in vitro culture conditions. However, a partial in-
duction of this phenotype (an altered specificity of cytosolic
proteolysis and a slow degradation of IAP molecules) was
Figure 9. Selection of apoptosis resistance and delayed degradation of
XIAP and c-IAP-1 during tumor growth (a) EL-4 control, EL-4ad, and
EL-4/tumor cells were treated with 1  M Nocodazole and induction of
apoptosis was monitored by the detection of DNA fragmentation. DNA
was purified from the cells and separated by a 1.8% agarose gel. (b) West-
ern blotting of XIAP and c-IAP-1 in cells treated with etoposide for the
indicated length of time. 5  g of protein was loaded in each lane. Western
blotting of  -actin was used as loading controls. (c), EL-4 control, EL-4ad,
EL-4/tumor (derived from in vivo tumors), or C57Bl/6 ConA blasts
were incubated for 30 min at 42 C and degradation of ubiquitin-conju-
gates was followed for up to 16 h with Western blot with anti-ubiquitin.T
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observed in apoptosis resistant EL-4 cells derived from large
subcutaneous in vivo tumors.
As growth of EL-4 tumors in vivo was limited by apop-
tosis susceptibility, our data are in line with the previously
reported high expression of 20S proteasomes in rapidly
proliferating cells (21, 22, 44). Apoptosis resistance may be-
come even more important than rapid proliferation during
growth under suboptimal conditions, such as low nutrition
and limited oxygen supply (23, 43). It was recently pro-
posed that the tumor microenvironment may drive the se-
lection of apoptosis resistant cells, especially in the presence
of hypoxia (43). We find that adaptation to growth in
starving culture conditions in vitro causes a phenotype in
EL-4 cells including TPP II up-regulation, poor degrada-
tion of c-IAP-1, and rapid tumor growth in vivo (Fig. 10).
This may suggest a link between the microenvironment
and signals that alter the specificity of intracellular proteoly-
sis. Although mouse tumors grafted experimentally can
proliferate to kill an animal within weeks, clinical tumors
develop over the course of years, and the problems to apply
certain promising tumor therapies may be related to this
difference in growth profile (45, 46). Thus, the study of tu-
mor survival mechanisms, such as the one presented in this
paper, may be crucial to understand tumor progression, and
especially when studied over long periods of time. Mam-
malian cells have a considerable over-capacity for proteaso-
mal proteolysis when compared with what is necessary for
proliferation in vitro. Up to 80% of the rate-limiting chy-
motryptic activity of the proteasome can be inhibited in
wild-type HeLa cells without any accumulation of ubiqui-
tinated proteins (5). This excess capacity may be present for
rapid removal of mis-folded proteins during cellular stress,
or potentially for rapid degradation of regulatory factors.
Our findings indicate that modulation of this over-capacity
alters the transduction of signals that depend on ubiquitin-
dependent protelysis. More specifically we found that a re-
duction of this capacity is a signal that leads to apoptosis re-
sistance in EL-4 tumor cells.
A large number of tumors overexpress IAP-family mem-
bers and these are believed to be involved in failure of tu-
mor therapy by causing resistance to cellular stress (16–18,
32–35). Overexpression of Survivin is observed in most tu-
mor cells and inhibits apoptosis during the G2/M phase by
inhibiting caspases, and is also involved in chromosomal
segregation and exit from mitosis (16, 47). We have ob-
served increased chromosome numbers in several indepen-
dent lines of EL-4ad cells, in comparison to EL-4 control
cells (unpublished data). Although the apoptosis resistance
and adaptation to low proteasomal activity in EL-4ad cells
is reversible it may thus predispose for the accumulation of
genetic, and therefore irreversible, damage. This may also
be explained by the involvement of N-end rule degrada-
tion of chromosomal cohesins, as the absence of this path-
way causes a loss of chromosomes in yeast mutants (48).
Although EL-4ad cells maintain the turn-over of proteins,
the presence of low proteasomal activity makes full control
of cellular physiology more difficult to achieve. The precise
control of ubiquitin-dependent pathways observed in nor-
mal cells may not be preferred by tumor cells, which could
instead benefit from an imprecise control during selection
of malignant characteristics.
The most well studied system with respect IAP mole-
cules may be Drosophila, which express DIAP-1, DIAP-2,
and a homologue of surririn (49). Results from this system
show that the genes controlling IAP stability (Grim, Hid,
and Reaper; reference 49) have a profound impact on
apoptosis susceptibility, perhaps more profound compared
with ectopic expression of the IAPs themselves (15, 50).
Thus, although a high steady-state level of IAPs before
apoptosis may cause a delay in transduction of the apoptotic
Figure 10. Induction of TPP II activity
and rapid tumor growth by adaptation to
cellular starvation. (a) EL-4 cells incubated
in cell culture medium diluted with PBS
were lysed, and high molecular weight cy-
tosolic proteins were analysed by Western
blot for TPP II expression. (b) EL-4 cells
and EL-4 cells growing in starvation me-
dium were exposed to etoposide and degra-
dation of c-IAP-1 was followed by Western
blotting analysis. (c) The high molecular
weight cytosolic fractions in (a) were ana-
lyzed for cleavage of AAF-AMC. The inhib-
itors NLVS and AAF-CMK were included
as controls. (d-e) EL-4 cells and EL-4 cells
adapted to growth in starvation medium
were grafted to irradiated C57Bl/6 mice at
106 (d) or 104 (e) cells per mouse.T
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signal, this may not prevent eventual removal of these mol-
ecules. Similarly, in several studies where XIAP have been
transfected into mammalian tumor cells this has created
only a partial protection from apoptosis, which probably
reflects that XIAP was still rapidly degraded upon apoptosis
triggering (13, 51). An increase in IAP stability may there-
fore be essential for apoptosis resistance also in naturally oc-
curring tumor cells. Thus, although comparisons between
insect and mammalian IAPs should be made with care, the
IAP biology in Drosophila may give important information
of relevance for apoptosis resistance in mammalian cells. In
reverse, a similar shift in specificity of cytosolic proteolysis,
as reported here in mouse tumor cells, is possible also in
Drosophila since TPP II is reported and has been cloned
from this species (52).
Proteasomal inhibition has previously been linked to dis-
ease pathogenesis, either as a pharmacological side-effect or
as a the consequence of a failure of protein degradation. A
partial proteasomal inhibition is reported as a possible side
effect causing hyper-lipidemia in patients treated with HIV
protease inhibitors (53, 54). Further, in neuro-degenerative
disease, proteins containing poly-Glutamine repeats assem-
ble into aggregates that also contain ubiquitin and 20S pro-
teasomes (55, 56). These aggregates are believed to cause
inhibition of the ubiquitin-proteasome pathway with
apoptosis as a consequence (56). In addition, Burkitt lym-
phoma cells have reduced proteasomal activity and in-
creased TPP II activity, a phenotype controlled by c-myc
overexpression in lymphoblastoid cell lines (20). Our re-
sults suggest that this phenotype may be linked to tumor
malignancy, which is interesting in view of the frequent
up-regulation of c-myc in naturally occurring tumors (57).
We show that an altered specificity of cytosolic proteolysis
disturbs the transduction of signals transmitted by ubiq-
uitin-dependent proteolysis. Our data point to the involve-
ment of IAP molecules in suppression of apoptosis in tu-
mors that reduce proteasomal activity. The participation of
other regulatory factors in this apoptosis resistance is how-
ever not excluded. Future studies may address whether an
altered specificity of cytosolic proteolysis contributes to the
acquisition of malignant characteristics in other tumor cells.
More specifically, the status of the ubiquitin-proteasome
pathway of tumors with up-regulation of IAP family mole-
cules merits further study.
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